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We have previously reported that the single nucleotide polymorphism (SNP) rs12553612 in IFNA8 is associated with
better overall survival of glioma patients with the AA-genotype compared with patients with the AC-genotype. As
rs12553612 is located in the IFNA8 promoter, we hypothesized that the A-allele allows for an enhanced IFNA8 promoter
activity compared with the C-allele. Reporter assays in the human monocyte derived THP-1 cell line demonstrated a
superior promoter activity of the A-allele compared with the C-allele. Electrophoretic mobility shift assays (EMSA) further
demonstrated that the A-genotype specifically binds to more nuclear proteins than the C-genotype, including the
transcription factor Oct-1. Further, co-transfection of plasmids encoding Oct-1 and the reporter constructs revealed that
Oct-1 enhanced the promoter activity with the A- but not the C-allele. Taken together, our data demonstrate that the
A-allele in the rs12553612 SNP, which is associated with better glioma patient survival, allows for IFNA8 transcription by
allowing for Oct-1 binding, which is absent in patients with C allele, and suggests a molecular mechanism of IFNA8
mediated immune-surveillance of glioma progression.
Introduction
Malignant gliomas are the most common primary brain tumors
with dismal prognosis. As information about their etiology and
the prognostic factors that influence patients’ survival is still
limited, it is critical to better understand the critical biological
interactions that regulate glioma development and growth.
A growing line of evidence supports significant roles of
immunosurveillance for prevention and regulation of cancer
development. For example, tumor infiltrating T-cells are capable
of killing tumor cells1 and are a positive prognostic factor for
cancer patients.1 Among a variety of cytokines and their signaling
pathways, the Type I interferons (IFNs), IFNa and IFNβ, appear
to play a key role in this regard. Although they have been long
known to induce tumor cell apoptosis and angiogenesis
inhibition,2 hematopoietic cells in the host (rather than tumor
cells) are the crucial targets of the antitumor activity of
endogenous Type-1 IFNs,3,4 More recent studies with melanoma
have demonstrated that host type I IFNs are critical for the innate
immune recognition of a growing melanoma through signaling on
CD8a+ dendritic cells (DCs).5,6
A SNP is a single nucleotide variation that occurs within a gene
of members of the same species. Several SNPs in immune
regulatory genes correlate with glioma risks and/or prognosis.7-9
Previous studies have shown a significant impact of SNPs in
innate immune pathways, such as ones in Toll-like receptor
(TLR) 3,10,11 TLR412 as well as interleukin-4 receptor (IL-4Ra),
which is associated with differential risk and prognosis of
glioblastoma multiforme.8,13 Recently, we reported a previously
undefined protective role of the Type-1 IFN pathway in the
surveillance against de novo mouse gliomas and that SNPs in
IFNAR1 and IFNA8 are associated with significantly altered
overall survival of patients with WHO Grade II and III gliomas.7
Specifically, the SNP rs12553612 is located at 335 base pairs (bp)
upstream of the IFNA8 initiation codon, which is in the putative
IFNA8 promoter region. As a SNP in a promoter region may
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affect the promoter activity and therefore the gene expression
levels,14 we hypothesized that the SNP in the IFNA8 promoter
(rs12553612) affects the interaction of transcription factors with
the DNA region involving the SNP, thereby affecting the activity
of the IFNA8 promoter.
Here we report that the A-genotype of rs12553612 in the
IFNA8 promoter which is associated with favorable overall
survival of glioma patients confers a better promoter activity
than the C-genotype. While in silico analysis predicts
multiple DNA binding proteins to bind to this site, we
found that probable factors C-Krox and Elk-1 did not
regulate promoter activity. However Oct-1 binds to the
DNA promoter segment containing the A-genotype and
overexpression of Oct-1 in THP-1 cells enhanced the
promoter activity. These data suggest a possible biological
mechanism underlying the enhanced IFNA8 expression in
glioma patients with the A-SNP (rs12553612) in the IFNA8
promoter resulting in better prognosis.
Results
The A-genotype leads to superior promoter activity
compared with the C-genotype. Glioma patients with the
AA-genotype in the rs12553612 SNP in the IFNA8
promoter exhibit prolonged overall survival compared with
patients with the AC-genotype.7 Additionally, as type-I IFNs
promote immune cell functions, we examined whether
IFNA8 promoter activities in the A-genotype were superior
to those in the C-genotype. To understand the underlying
molecular basis, we created IFNA8 promoter luciferase
constructs by cloning the promoter region of IFNA8
(-1528~-27 upstream the IFNA8 precursor) with either A
or C at position -335 into the pGL4.20 luciferase vector at
the XhoI and HindIII sites in the multiple cloning site.
Human monocyte derived THP-1 cells were co-transfected
with these Firefly luciferase reporter plasmids with the A- or
C- genotype (Fluc) and Renilla luciferase plasmid for internal
control (Rluc). Relative luciferase activities (Fluc/Rluc) were
obtained at 24 h after the co-transfection (Fig. 1). We found
that the IFNA8 A-genotype reporter plasmid demonstrated
significantly higher activity than the C- genotype. The
immunoadjuvant polyinosinic-polycytidylic acid stabilized
by lysine and carboxymethylcellulose (poly-ICLC) has been
shown to enhance the efficacy of glioma vaccines, as we
Figure 1. Interferon (IFN)-A8 promoter activity with the A-genotype
at -335 is superior to that with the C-genotype. (A) 1  105 THP-1
cells were co-transfected with 0.02 mg of pGL4 vector encoding
Renilla luciferase (Rluc) as internal control and 0.18 mg of pGL4
vector encoding Firefly luciferase downstream of IFNA8 promoter
with A- or C-genotype (A-Fluc and C-Fluc). Twenty-four hours after
the co-transfection, luc activity was measured from triplicate
cell-lysates and relative luciferase was calculated (Fluc/Rluc).
(B and C) Twenty-four hours after the co-transfection, the cells
were stimulated with either (B) 10 mg/ml of LPS or (C) 10 or
50 mg/ml of poly-ICLC. Two hours after the stimulation, relative
luciferase activity was measured. Results are from one of three
experiments with similar results. The p value was calculated by
an unpaired two-tailed Student’s t-test. Error bars indicate
standard deviation among triplicate samples.
488 OncoImmunology Volume 1 Issue 4
© 2012 Landes Bioscience.
Do not distribute.
previously demonstrated in glioma-bearing mice15,16 and
humans.17 As poly-ICLC and lipopolysaccharide (LPS) are potent
inducers of Type-I IFNs, we further examined whether they could
enhance IFNA8 promoter activity of the A and C genotype.
Following 2 h treatment with 10 mg/ml poly-ICLC or LPS,
THP-1 cells still exhibited increased activity of the A-genotype
IFNA8 promoter over the C-genotype in the presence of LPS
(Fig. 1B) or poly-ICLC (Fig. 1C).
The A-genotype IFN-A8 promoter specifically binds more
nuclear proteins than the C-genotype. We hypothesized that the
observed differential activities of the promoter constructs
reflecting the two SNPs were mediated by altered binding of
transcription factors at the site of SNPs. We therefore extracted
nuclear proteins from THP-1 cells and incubated them
with biotin-labeled 40-mers derived from the IFNA8 promoter
(nucleotide -354 to -314) with either A- or C- genotype. By using
EMSA to detect protein bound DNA, we found that the probe
with A-genotype SNP binds to either more protein and/or with a
higher affinity than the C-genotype SNP (Fig. 2A) as seen in both
the shifted blot and densitometry plot. To demonstrate that the
observed binding is sequence-specific, a competition assay was
conducted using 200-fold more non labeled (but otherwise
identical) 40-mers added to the sample. Indeed, the protein-DNA
interaction was specific as the non labeled competitive inhibitors
blocked the binding of protein both with the A- and C- genotype
(Fig. 2B).
Transcription factor Oct-1 binds and enhances the promoter
activity of the IFNA8 A-genotype. On the basis of predicted
binding sites to the promoter region, we next performed a
supershift assay to determine which proteins bind in greater
amounts to the A-genotype. We selected Oct-1 and Elk-1 as our
in silico analysis with TFsearch18 predicted that Oct-1or Elk-1
may bind to this region. Further, TFsearch predicted that Oct-1
would bind to the A- but not C- genotype. Surprisingly, although
Elk-1 is expressed in THP-1 cells (not shown) we could not detect
any supershift in either the A- or C-genotype when THP-1
nuclear protein extracts were pre-incubated with Elk-1 specific
antibody (Fig. 3A). However, when the nuclear extracts were
incubated with Oct-1 antibody we observed a supershift in the A-
but not C- genotype, suggesting the binding of Oct-1 to the
IFNA8 promoter, as predicted in silico. These results suggest that
Oct-1 may be the transcription factor involved in the activation of
IFNA8 promoter, and failure of Oct-1 to bind to the C-genotype
results in lower IFNA8 activity.
We further assessed whether overexpression of Elk-1 or Oct-1
could lead to enhanced activity of the IFNA8 promoter. We
therefore performed a promoter luciferase assay using the IFNA8
promoter A- genotype. Consistently, overexpression of Oct-1 but
not Elk-1 lead to a statistically significant increase in luciferase
activity of the IFNA8 promoter (Fig. 3B), further supporting the
role of Oct-1 in the differential IFNA8 promoter activities
between the A- and C- genotype.
Discussion
We described herein that the A-genotype in the IFNA8 promoter
SNP rs125553612 confers a better promoter activity compared
with the C-SNP. As we previously reported that WHO Grade
II-III glioma patients with the AA-genotype have better overall
survival than patients with the AC-alleles, higher IFNa8
expression levels may indeed contribute to the better survival of
patients. Through a series of experiments, we provide the
following molecular mechanism to explain this observation. As
depicted by Figure 4, the rs12553612 SNP results in a change of
Oct-1 binding site of IFNA8 promoter at position -335, a change
at this site from A to C allele causes substantial loss of
Figure 2. The DNA probe with the A-genotype in the IFNA8 promoter demonstrates higher binding to THP-1 nuclear lysate than one with
the C-genotype by EMSA. (A) An EMSA was performed with biotin labeled DNA 40mers (20 fmol) with either the A-genotype or C-genotype SNP using
THP-1-derived nuclear lysate (10 mg). Lane 1, A-genotype DNA alone; Lane 2, A-genotype DNA incubated with protein lysate; Lane 3, C-genotype DNA
alone; Lane 4, C-genotype DNA incubated with protein lysate. Quantification of the bands in Lanes 2 and 4 was done using ImageJ (National Institutes of
Health) software. (B) A competition assay with or without 200-fold excess non-labeled A- or C-genotype DNA over the biotin labeled SNP DNA to
compete specifically with DNA binding site or EBNA DNA (control). Quantification of the bands was done using ImageJ (National Institutes of Health)
software. Results are from one of three experiments with similar results.
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transcription factor Oct-1 binding affinity to the promoter
resulting in downregulation of IFNA8 transcription. As we have
shown before, Type I IFN signaling plays a major role in
promoting anti-glioma immune surveillance.7 Thus a decreased
IFNA8 transcription activity may potentially affect the immune
surveillance resulting in lower survival. Using overexpression
experiments, we demonstrated that Oct-1 but not Elk-1 regulates
the IFNA8 promoter activity in the A- but not C- genotype.
Little is known about the roles and regulation of the individual
IFNA genes of which there are 14 in humans. To date the
primary activators of IFNA promoters that have been described
are interferon regulatory factor (IRF) family members.19 For
example, upon Newcastle disease virus (NDV) infection, infected
cells overexpress IRF-5 that induced IFNA8.20 Therefore, IRF-5
may be a key transcription factor for IFNA8. However, IRF-5 can
act as both an activator and a repressor of IFN gene induction
dependent on the IRF-interacting partner including IRF-3 and
IRF-7.20 Further, IFNA8 has been suggested to have the most
potent anti-tumor activity in chronic myelogenous leukemia
(CML)-derived cell lines21 suggesting the importance of IFNA8.
Our data demonstrate that Oct-1 can bind and promote
IFNA8 promoter activity. Oct-1, also known as POU domain
Class 2 transcription factor 1 (POU2F1) is known to be post
transcriptionally regulated at least in part by p34cdc2-related
protein kinase which is active during mitosis as well as multiple
other kinases and phosphatases.22 Thus activated proliferating
immune cells may have enhanced Oct-1 activity which can lead
directly to Type-I IFN production. Other studies have demon-
strated additional mechanisms by which Oct-1 function is
regulated, such as Hydrogen peroxide which can stimulate
the nuclear import of Oct-123 and the glucocorticoid
receptor (GR) which can synergize with Oct-1 and promote
recruitment of the complex (Oct-1-GR) to glucocorticoid
response elements on DNA.24 Oct-1 can also be activated
in response to DNA damage.25 These may still be partial
mechanisms with which Oct-1 is regulated in glioma tissues
and IFNA8 is induced in patients with the A-genotype.
Interestingly, Oct-1 can inhibit IRF-7- and IRF-3-mediated
IFNA11 expression in a virus infection model.26 Further
investigations are warranted to evaluate the role of Oct-1 in
the entire Type-I IFN families and anti-tumor immunity.
Further investigations using samples obtained from
human donors with AA-, AC- or CC-genotype would have
strengthened our study. However, unfortunately, analysis of
patient samples was not feasible as we have previously
reported that of about 300 patients analyzed few patients
Figure 4. Schematic demonstrating the OCT-1 binding ability to the IFNA8
promoter region containing the rs12553612 SNP.
Figure 3. The A-genotype demonstrates superior binding to OCT-1 compared with the C-genotype. (A) Supershift assay was performed by
pre-incubation of THP-1 cell nuclear lysate with either anti-ELK-1 or OCT-1mAb prior to DNA binding assay. Lanes 1–4, A-genotype DNA probe;
Lanes 5–8, C-genotype DNA probe, Lanes 1 and 5, DNA probes alone; Lanes 2 and 6, DNA probes incubated with THP-1 lysate alone; Lanes 3 and 7,
DNA probes with THP-1 lysate preincubated with anti-ELK-1 mAb; Lanes 4 and 8,DNA probes with THP-1 lysate preincubated with anti-OCT-1 mAb.
The supershifted bands are marked with arrows. (B) THP-1 cells were transfected with the A-genotype Fluc-reporter plasmid and the internal control
Rluc plasmid as well as an expression plasmid encoding either ELK-1, OCT- or IRF-7 as a positive control. Relative Luciferase was calculated as Fluc/Rluc.
Results are from one of two experiments with similar results. * Indicates that the values were statistically different (p , 0.05) from the control samples
with the empty vector by unpaired two-tailed Student’s t-test. Error bars indicate standard deviation among triplicate sample
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(n = 9) have the AC-genotype and we identified no individuals
with the CC-genotype.7 Accordingly, the National Center for
Biotechnology Information (NCBI) database for the current SNP
(rs12553612) indicates that among a total 947 individuals
analyzed AA-, AC- and CC-genotypes were found in 719, 122
and 14 individuals, respectively, with a dominant prevalence of
AC and CC genotypes in Asian populations (http://www.ncbi.
nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=12553612#Diversity).
Taken together, our data suggest that Oct-1can regulate IFNA8
promoter in the A-genotype but not the C-genotype allele. We
predict based on our data that patients with the AA-genotype
should have higher expression of IFNA8 than patients with the
AC- or CC-genotype.
Materials and Methods
Reagents. RPMI 1640, fetal bovine serum (FBS), L-glutamine,
sodium pyruvate, 2-mercaptoethanol, nonessential amino acids,
and penicillin/streptomycin and all reagents for DNA transfection
were purchased from Invitrogen, including Lipofectamine 2000
(11668-02), with the exception of Luciferase reporter genes
and dual-Luciferase reporter assay system, which were from
Promega (E1910). Plasmids containing human cDNA clones
were purchased from Origene. Oligonucleotides for the IFNA8
electrophoretic mobility shift assays (EMSA) were obtained from
Integrated DNA technologies; EMSA were done using the
Thermo LightShift Chemiluminescent EMSA Kit (20148).
Oct-1 (clone C-21, sc-232) and Elk-1 (cloneI-20, sc-355)
antibodies were purchased from Santa Cruz Biotechnology.
Cell culture. The THP-1 human monocyte cell line was
maintained in complete medium (RPMI 1640) supplemented
with 10% heat-inactivated FBS, 50 units/mL penicillin,
50 mg/mL streptomycin, 1 mM sodium pyruvate, 55 mM
2-mercaptoethanol, and MEM non-essential amino acids (Life
Technologies Invitrogen) in a humidified incubator in 5%
CO2 at 37°C.
DNA transfection. Mixture of plasmid-DNA (pDNA) was
prepared as 0.08–0.2 mg (total pDNA value)/ 25 ml/well.
Usually, 0.02 mg/well pGL4.73 (hRluc/SV40) vector (Rluc) as
internal control and 0.06–0.18 mg/well pGL4.20 (luc2/Puro)
vector (Fluc) containing the A- or C-genotype of IFNA8
promoter gene were combined with diluted Lipofectamine 2000
(0.5 ml/well), and incubated for 20 min at room temperature.
After the incubation, the complexes were added to each well
containing 1  105 THP-1 cells and incubated at 37°C in a
CO2 incubator for 24 h. During the incubation, 100–150 ml/well
complete medium was added 18–20 h after the transfection.
When using stimulant such as poly-ICLC (Oncovir, Inc.) and
LPS, the stimulant was added 2 h before stopping the incubation.
Dual-luciferase assay. Cultured cells with complexes for
DNA transfection were centrifuged at three times at 1,500 rpm
for 2–3 min. 80 ml/well passive lysis buffer (PLB) was added
into the well containing the pellet and incubated for 15 min
at room temperature. Aliquots of PLB lysate (20 ml) were
transferred into luminometer tube containing 70 ml of LARII
and inserted into luminometer machine to measure Fluc activity.
After addition of 100 ml of Stop&Glo Reagent, Rluc activity
was measured immediately. Relative Luciferase activity [A- (or
C-) Fluc/A- (or C-) Rluc]/(untreated C-Fluc/untreated C-Rluc)
was measured using OD data from triplicate cell-lysates.
Electrophoretic mobility shift assay (EMSA). The non-
radioactive LightShift Chemiluminescent EMSA Kit (Thermo,
20148) was used to detect DNA-protein interactions. The 5'
biotin end-labeled DNA oligonucleotides each containing one
SNP in the IFNA8 promoter was used as a probe for the EMSA.
The probe DNAs were 40-bp double stranded DNA made by
annealing (95°C for 5 min) single stranded oligonucleotides
for the A SNP (5'-Biotin-TAGGAATGTAGTACATTCAAA
TATGT GCATAATATATCTG and 5'-Biotin CAGATATA
TTATGCACATATTTG AATGTACTACATTCCTA) and the
C SNP (5'-Biotin-TAGGAATGTAGTACATT CACATATGT
GCATAATATATCTG and 5'-Biotin-CAGATATATTATGCA
CAT ATGTGAATGTACTACATTCCTA). Specificity was
determined by a competition assay with the addition of
200 molar excess of unlabeled double stranded IFNA8 promoter
oligonucleotide.
Nuclear extracts (10 mg) were isolated from the THP-1
human monocyte cell line using the Thermo Subcellular
Protein Fractionation Kit (Thermo, 7884) and protein con-
centration was determined by the Bradford assay. Aliquots of
nuclear extracts (10 mg) were incubated with 20 femtomole
(fM) AT or GC IFNA8 probe in 1 binding buffer, 500 mM
KCl, 0.1% NP40, 2.5% glycerol, 50 ng/ml poly dI-dC and 5 mM
MgCl2 for 20 min and were then electrophoresed through a
6% DNA retardation gel at 70V for ~45 min. For the supershift
assay, nuclear extracts were incubated with antibodies for Elk-1
or Oct-1 for 2 h on ice prior to incubation with probes. The
gels were electrophoretically transferred at 380 mA for 1 h on
ice to a positively charged nylon membrane and immediately
cross-linked for 15 min with a UV transilluminator equipped
with a 312 nm bulb. Streptavidin-horseradish peroxidase con-
jugate and the LightShift Chemiluminescent Substrate (Thermo,
89880) were used to detect the biotin end-labeled DNA. The
nylon membranes were exposed to X-ray film for 0.5–2 min for
detection of the signal.
Statistical analyses. The statistical significance (p value) of
differences between groups was calculated by unpaired two-
tailed Student’s t-test. Differences were considered as significant
when p , 0.05. All statistical analyses were performed on
Graphpad Prism software.
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